18,710 Shares in Mirum Pharmaceuticals, Inc. $MIRM Purchased by SG Americas Securities LLC

SG Americas Securities LLC acquired a new stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 18,710 shares of the company’s stock, valued at approximately $1,478,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Eventide Asset Management LLC increased its stake in shares of Mirum Pharmaceuticals by 4.4% in the second quarter. Eventide Asset Management LLC now owns 2,637,485 shares of the company’s stock valued at $134,224,000 after purchasing an additional 110,485 shares during the period. Wellington Management Group LLP boosted its position in shares of Mirum Pharmaceuticals by 566.8% during the third quarter. Wellington Management Group LLP now owns 790,689 shares of the company’s stock worth $57,965,000 after buying an additional 672,118 shares during the period. Boone Capital Management LLC boosted its position in shares of Mirum Pharmaceuticals by 6.3% during the second quarter. Boone Capital Management LLC now owns 641,448 shares of the company’s stock worth $32,643,000 after buying an additional 38,130 shares during the period. Arrowstreet Capital Limited Partnership grew its holdings in Mirum Pharmaceuticals by 709.5% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 612,318 shares of the company’s stock worth $44,889,000 after buying an additional 536,674 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. grew its holdings in Mirum Pharmaceuticals by 17.0% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 495,976 shares of the company’s stock worth $36,360,000 after buying an additional 72,232 shares in the last quarter.

Analysts Set New Price Targets

MIRM has been the topic of several recent analyst reports. Wall Street Zen downgraded Mirum Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Saturday, February 28th. Leerink Partners decreased their price target on Mirum Pharmaceuticals from $120.00 to $118.00 and set an “outperform” rating for the company in a research note on Thursday, February 26th. Stifel Nicolaus lifted their price objective on shares of Mirum Pharmaceuticals from $98.00 to $125.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. Robert W. Baird upped their price objective on shares of Mirum Pharmaceuticals from $80.00 to $88.00 and gave the stock an “outperform” rating in a report on Monday, December 8th. Finally, TD Cowen increased their target price on shares of Mirum Pharmaceuticals from $117.00 to $125.00 and gave the company a “buy” rating in a research report on Friday, March 27th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $117.67.

Mirum Pharmaceuticals Stock Performance

MIRM opened at $96.24 on Tuesday. The business has a 50 day moving average price of $96.28 and a two-hundred day moving average price of $82.59. The company has a debt-to-equity ratio of 0.98, a current ratio of 2.67 and a quick ratio of 2.55. The company has a market capitalization of $5.81 billion, a price-to-earnings ratio of -200.50 and a beta of 0.51. Mirum Pharmaceuticals, Inc. has a 1-year low of $36.88 and a 1-year high of $109.28.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings results on Wednesday, February 25th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.13). The firm had revenue of $148.93 million for the quarter, compared to analyst estimates of $141.78 million. Mirum Pharmaceuticals had a negative net margin of 4.48% and a negative return on equity of 8.53%. The firm’s revenue for the quarter was up 49.8% compared to the same quarter last year. During the same quarter last year, the business posted $1.00 earnings per share. Research analysts predict that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current fiscal year.

Insider Activity

In other news, COO Peter Radovich sold 16,515 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $91.98, for a total value of $1,519,049.70. Following the transaction, the chief operating officer owned 40,272 shares of the company’s stock, valued at $3,704,218.56. The trade was a 29.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Joanne Quan sold 7,287 shares of the business’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $91.98, for a total transaction of $670,258.26. Following the completion of the sale, the insider owned 18,864 shares in the company, valued at $1,735,110.72. The trade was a 27.87% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 121,942 shares of company stock valued at $11,416,645 over the last quarter. Insiders own 14.36% of the company’s stock.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.